| Background |
Dr Hill is a consultant oncologist at the Royal Berkshire Hospital, Reading. She is a core member of the upper GI and lower GI cancer multidisciplinary teams at the Royal Berkshire and has strong working relationships with the Oxford oesophagogastric and hepato-biliary teams. She has a special clinical interest in upper gastrointestinal (GI) and lower gastrointestinal cancers. Dr Hill has a broad range of skills and experience. She has a sub-specialty interest in the management of oesophageal, gastric, liver, pancreatic, colorectal, anal cancers and cancers of unknown primary origin, with extensive experience of treating such patients with radiotherapy and systemic therapy. Dr Hill is co-investigator for the ADD-ASPIRIN trial and principal investigator (PI) for the SCOPE-2 trial. She has a significant portfolio of published work and has received several awards for her research. She has implemented modern radiotherapy techniques such as IMRT and 4DCT for upper GI cancers and is the clinical lead for SABR treatment of oligometastatic disease at the Royal Berkshire Hospital. She is also the Cancer of Unknown Primary Clinical Lead. |
|---|---|
| Specialties | |
| Languages Spoken |
English |
| Areas of Expertise |
Oesophageal, stomach, pancreatic, biliary, liver, colorectal, and anal cancers; cancers of unknown primary origin; chemotherapy, radiotherapy, and immunotherapy. |
| Medical Training |
Qualifications:
DPhil in Radiobiology, University of Oxford (2015)
FRCR, Royal College of Radiologists (2009)
MRCP, Royal College Physicians (2004)
MSc (Oncology), Institute of Cancer Research, University of London (2009)
MBChB, University of Birmingham (2001)
BSc (Intercalated), University College London (1998)
Additional training: Proton Therapy Clinical Education Programme Penn Medicine 2021 GMC registration: Reference number 6025316
Clinical Oncology, 2015 |
| Current Posts |
Consultant Oncologist |
| Sites Worked at |
Royal Berkshire Hospital |